Kihealth Raises $5M in Oversubscribed Seed Round to Launch First-of-Its-Kind Diabetes Diagnostic

The funding supports the commercial rollout of Kihealth’s first laboratory-developed, minimally-invasive test that measures biomarkers of beta cell apoptosis, the earliest marker of insulin resistance and chronic diseases such as diabetes